FREQUENCY OF COMMON COMPLICATIONS DURING TREATMENT OF PATIENTS WITH BENIGN PROSTATE HYPERPLASIA (BPH)

  • Zoran Kričković doktor
Keywords: Prostate, benign hyperplasia, prostatic obstruction, complications

Abstract


Background: Benign prostatic hyperplasio (BPH) is a very common disease in older men. BPH involves the presence of signs of hyperplasia of the stromal and epithelial elements in the prostate with consequent enlargement of its volume.

The aim of study: The aim of this study is to analyze the frequency of typical complications in the treatment of patients with benign prostatic hyperplasia and the effect of medicamentous treatment.

Method:  Respondents whom were diagnosed BPH were included in the prospective, one-year study. Respondents were divided into 2 groups. The first group (30 respondents) consisted of respondents whose prostate volume was over 50 cc, and the second group (30 respondents) was consisted of subjects with prostate volume less than 50 cc.

The complications of BHP analyzed are: residual urine (RU), symptomatic urinary infection, hematuria, thickening of the detrusor wall, diverticulum in the bladder, ureterohydronephrosis, renal failure, bladder stone and acute urinary retention (AUR).

Results: The majority of respondents in both groups were aged 60-69. There was a statistically significant difference in the average value of RU between the groups at: the first, second and fifth examinations (p <0.05), as well as the complication of symptomatic urinary infection, since the same occurred earlier in the first group than in the second group. (p <0.05). There was no statistically significant difference in complications: hematuria, detrusor wall thickening, and deverticulum (p> 0.05). Complications: ureterohydronephrosis, renal failure, bladder stone, and AUR were not diagnosed in either respondents in either group.

Conclusion: Relevant medical therapy leads to a reduction of RU and reduces the risk of complications caused by its presence. Other complications of BPH were rare or absent in both groups, suggesting that appropriate and timely applied medical therapy affects the course of BPH and reduces the risk of complications and the need for surgical treatment. Benefit from medicamentous therapy is equally represented in both analyzed groups of patients.

References

1. Barkin J. Management of Benign Prostatic Hyperplasia by the primary care phisician in the 21 st century: the new paradigm. Can J Urol 2008;15(1):21-30.

2. Vasanwala FF, Yuet Chen Wong M, Sun Sien Ho H, Tatt Foo K. Benign Prostatic Hyperplasia and male lower urinary symptoms: A guide for family physicians, Asian J Urol 2017; 4(3):181-184.

3. Geavlete P, Gheorghe N, Geavlete B. Minimally Invasive Treatment Algorithm for Benign Prostatic Hyperplasia, Endoscopic Diagnosis and Treatment in Prostate Pathology, Handbook of Endourology 2016.p.171-174.

4. Kappor A. Benign Prostatic Hyperplasia (BPH) Management in the primary care setting. Can J Urol 2012;19(1):10-17.

5. Luo GC, Foo KT, Kuo T, Tan G. Diagnosis of Prostate adenoma and the relationship between the site of Prostate adenoma and bladder outlet obstruction. Singap. Med J. 2013;54:482-486.

6. Kirby RS, Mc Connell JD. Benign prostataic hyperplasia. Offord; 1997.p.20.
7. Marković V. Bolesti prostate. Izd:Službeni list SRJ, Beograd, 2000.
8. Ezz El Din. Reliability of the I-PSS in the assessment of the patients with lower urinary tract symptoms and/or benign prostatic enlargement. J Urol 1996.p.156-987.

9. Ezz El Din. The corelation betwen bladder outlet obstruction and lower uriny tract symptoms as measured by the International Prostate Symptom Score (I-PSS ). J .Urol 1996.p.156-1020.
10. Khoury S. Wright F:Hormonologic de la prostate.Prostate 2. IFSI Paris; 1985.p.10.
Published
2020/03/27
Section
Original article